Seguir
Lu Chen
Lu Chen
Recursion Pharmaceuticals
Dirección de correo verificada de recursionpharma.com
Título
Citado por
Citado por
Año
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome
NT Ihle, LA Byers, ES Kim, P Saintigny, JJ Lee, GR Blumenschein, A Tsao, ...
Journal of the National Cancer Institute 104 (3), 228-239, 2012
5592012
Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma
MS Lionakis, K Dunleavy, M Roschewski, BC Widemann, JA Butman, ...
Cancer Cell 31 (6), 833-843. e5, 2017
4602017
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
JD Phelan, RM Young, DE Webster, S Roulland, GW Wright, M Kasbekar, ...
Nature 560 (7718), 387-391, 2018
3472018
Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro
Q Zhang, CZ Chen, M Swaroop, M Xu, L Wang, J Lee, AQ Wang, ...
Cell discovery 6 (1), 80, 2020
2242020
Small molecule compounds targeting miRNAs for cancer therapy
PC Monroig, L Chen, S Zhang, GA Calin
Advanced drug delivery reviews 81, 104-116, 2015
1692015
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
GL Lin, KM Wilson, M Ceribelli, BZ Stanton, PJ Woo, S Kreimer, EY Qin, ...
Science translational medicine 11 (519), eaaw0064, 2019
1592019
Targeting microRNAs with small molecules: from dream to reality
S Zhang, L Chen, EJ Jung, GA Calin
Clinical Pharmacology & Therapeutics 87 (6), 754-758, 2010
1562010
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
A Thomas, N Takahashi, VN Rajapakse, X Zhang, Y Sun, M Ceribelli, ...
Cancer Cell 39 (4), 566-579. e7, 2021
1262021
From laptop to benchtop to bedside: structure-based drug design on protein targets
L Chen, J K Morrow, H T Tran, S S Phatak, L Du-Cuny, S Zhang
Current pharmaceutical design 18 (9), 1217-1239, 2012
1122012
Synergistic and Antagonistic Drug Combinations against SARS-CoV-2
T Bobrowski, L Chen, RT Eastman, Z Itkin, P Shinn, CZ Chen, H Guo, ...
Molecular Therapy 29 (2), 873-885, 2021
110*2021
A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells
Y Chen, CA Tristan, L Chen, VM Jovanovic, C Malley, PH Chu, S Ryu, ...
Nature Methods 18 (5), 528-541, 2021
812021
An OpenData portal to share COVID-19 drug repurposing data in real time
KR Brimacombe, T Zhao, RT Eastman, X Hu, K Wang, M Backus, ...
bioRxiv, 2020
782020
Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma
Y Fu, DJ Urban, RR Nani, YF Zhang, N Li, H Fu, H Shah, AP Gorka, ...
Hepatology 70 (2), 563-576, 2019
752019
Novel insights of structure-based modeling for RNA-targeted drug discovery
L Chen, GA Calin, S Zhang
Journal of chemical information and modeling 52 (10), 2741-2753, 2012
632012
A critical assessment of combined ligand-and structure-based approaches to HERG channel blocker modeling
L Du-Cuny, L Chen, S Zhang
Journal of chemical information and modeling 51 (11), 2948-2960, 2011
632011
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma
CM Heske, MI Davis, JT Baumgart, K Wilson, MV Gormally, L Chen, ...
Clinical Cancer Research 23 (23), 7301-7311, 2017
542017
Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs
I Vannini, PM Wise, KB Challagundla, M Plousiou, M Raffini, E Bandini, ...
Nature communications 8 (1), 1801, 2017
432017
Recent development of anticancer therapeutics targeting Akt
J K Morrow, L Du-Cuny, L Chen, E J Meuillet, E A Mash, G Powis, ...
Recent patents on anti-cancer drug discovery 6 (1), 146-159, 2011
422011
SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
U Jo, Y Murai, S Chakka, L Chen, K Cheng, J Murai, LK Saha, ...
Proceedings of the National Academy of Sciences 118 (6), e2015654118, 2021
402021
Comprehensive modeling and discovery of mebendazole as a novel TRAF2-and NCK-interacting kinase inhibitor
Z Tan, L Chen, S Zhang
Scientific reports 6 (1), 33534, 2016
342016
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20